Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice

Innes, Helen; Lim, Sheow Lei; Hall, Allison; Chan, Su Yin; Bhalla, Neeraj; Marshall, Ernest

doi:10.1007/s00520-007-0334-8

Cited by 83 publications

(39 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been validated and shown to be useful in predicting outcomes in cancer patients with FN [11][12][13][14][15]. We observed similar findings, in that MASCC risk-index score was able to predict 90% of low-risk patients and 72% of high-risk patients.…”

Section: Discussionsupporting

confidence: 89%

Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia

Kim

Lee

Chun

et al. 2010

Support Care Cancer

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 89%

Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia

Kim

Lee

Chun

et al. 2010

Support Care Cancer

View full text Add to dashboard Cite

show abstract

“…The LOS for all FN patients was 8.7 days, which collaborates with other studies of 6.5-9.2 days (Courtney et al, 2007;Innes et al, 2008;Schelenz et al, 2012). Surprisingly, patients who were younger than 40 years old were more likely to need longer hospitalization period compared to the older groups.…”

Section: Discussionsupporting

confidence: 76%

“…The median cost of FN was THB 33,686 (USD 1,122) per inpatient episode. Although it is much lower than other studies from the US and UK (Courtney et al, 2007;Liou et al, 2007;Innes et al, 2008;Schelenz et al, 2012), it is a huge burden for the payers, the Thai government. The three main reimbursement programs for Thai citizens are national coverage, government welfare for government officers, and social welfare for workers.…”

Section: Discussionmentioning

confidence: 79%

Mortality, Length of Stay, and Cost Associated with Hospitalized Adult Cancer Patients with Febrile Neutropenia

Chindaprasirt¹,

Wanitpongpun²,

Limpawattana³

et al. 2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Febrile neutropenia (FN) is a serious complication following chemotherapy and is associated with significant mortality and financial expenditure. The aim of this study was to evaluate risk factors for longer length of stay (LOS) and mortality and cost of treatment among hospitalized adults with cancer who developed febrile neutropenia in Thailand. Materials and Methods: Information on illness of inpatients and casualties came from hospitals nationwide and from hospital withdrawals from the 3 health insurance schemes in fiscal 2010. The data covered 96% of the population and were analyzed by age groups, hospital level, and insurance year schemes in patients with febrile neutropenia. Results: A total of 5,809 patients were identified in the study. The mortality rate was 14%. The median LOS was 8.67 days and 69% of patients stayed for longer than 5 days. On bivariate analysis, age, cancer type, and infectious complications (bacteremia/sepsis, hypotension, fungal infections, and pneumonia) were significantly associated with longer LOS and death. On multivariate analysis, acute leukemia and infectious complications were linked with longer LOS and death significantly. The median cost of hospitalized FN was THB 33,686 (USD 1,122) with the highest cost observed in acute leukemia patients. Conclusions: FN in adult patients results in significant mortality in hospitalized Thai patients. Factors associated with increased mortality include older age (>70), acute leukemia, comorbidity, and infectious complications.

show abstract

“…BC patients with a history of FN had an increased risk of all-cause hospitalization in the first month after the febrile event compared with patients who never experienced FN (odds ratio (OR) = 23.0, 95% confidence interval (CI) 8.3-63.7) and they also had a longer median length of stay of all-cause hospitalizations (4 days vs. 1 day). Moreover, regardless of the type of cancer diagnosed, the length of hospital stay for FN patients is 6.5-8.8 days [46,47], with an overall cost of USD 15,231 per FN episode or USD 1,455 per day of hospitalization [48]. …”

Section: Discussionmentioning

confidence: 99%

Management of Breast Cancer Patients with Chemotherapy-Induced Neutropenia or Febrile Neutropenia

et al. 2014

View full text Add to dashboard Cite

Chemotherapy-induced neutropenia (CIN) is a common toxicity caused by the administration of anticancer drugs. This side effect is associated with life-threatening infections and may alter the chemotherapy schedule, thus impacting on early and long-term outcomes. Elderly breast cancer patients with impaired health status or advanced disease as well as patients undergoing dose-dense anthracycline/taxane- or docetaxel-based regimens have the highest risk of CIN. A careful assessment of the baseline risk for CIN allows the selection of patients who need primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) and/or antimicrobial agents. Neutropenic cancer patients may develop febrile neutropenia and CIN-related severe medical complications. Specific risk assessment scores, along with comprehensive clinical evaluation, are able to define a group of febrile patients with low risk for complications who can be safely treated as outpatients. Conversely, patients with higher risk of severe complications should be hospitalized and should receive intravenous antibiotic therapy with or without G-CSF.

show abstract

Management of febrile neutropenia in solid tumours and lymphomas using the Multinational Association for Supportive Care in Cancer (MASCC) risk index: feasibility and safety in routine clinical practice

Abstract: The MASCC risk index is both feasible and safe when used in standard clinical practice to guide the management of FN in patients with solid tumours and lymphomas. Patients predicted to have low risk can be managed safely with oral antibiotics and early hospital discharge.

Cited by 83 publications

References 14 publications

Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia

Predictive factors of poor prognosis in cancer patients with chemotherapy-induced febrile neutropenia

Mortality, Length of Stay, and Cost Associated with Hospitalized Adult Cancer Patients with Febrile Neutropenia

Management of Breast Cancer Patients with Chemotherapy-Induced Neutropenia or Febrile Neutropenia

Contact Info

Product

Resources

About